KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Cash & Equivalents (2016 - 2026)

Bristol Myers Squibb has reported Cash & Equivalents over the past 18 years, most recently at $9.6 billion for Q1 2026.

  • Quarterly Cash & Equivalents fell 11.96% to $9.6 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.6 billion through Mar 2026, down 11.96% year-over-year, with the annual reading at $10.2 billion for FY2025, 1.32% down from the prior year.
  • Cash & Equivalents was $9.6 billion for Q1 2026 at Bristol Myers Squibb, down from $10.2 billion in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $15.7 billion in Q3 2025 and troughed at $6.3 billion in Q2 2024.
  • The 5-year median for Cash & Equivalents is $9.6 billion (2026), against an average of $10.0 billion.
  • Year-over-year, Cash & Equivalents tumbled 42.88% in 2022 and then skyrocketed 100.21% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $9.1 billion in 2022, then rose by 25.66% to $11.5 billion in 2023, then decreased by 9.75% to $10.3 billion in 2024, then fell by 1.32% to $10.2 billion in 2025, then decreased by 6.22% to $9.6 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Cash & Equivalents are $9.6 billion (Q1 2026), $10.2 billion (Q4 2025), and $15.7 billion (Q3 2025).